Other news
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Cooperation RTM-Alliance Medical
It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...
Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...
RTM added as distributor NeuraCeq®
Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F...
Interested in a collaboration?
Contact us to discuss the possibilities.